The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term (8 years) assessment of trastuzumab-related cardiac events in the HERA trial.
Evandro De Azambuja
Honoraria - Roche
Marion Jennifer Procter
Research Funding - Roche
Dirk van Veldhuisen
No relevant relationships to disclose
Dominique Agbor-Tarh
No relevant relationships to disclose
Otto Metzger Filho
No relevant relationships to disclose
Jutta Steinseifer
Employment or Leadership Position - Roche
Michael Untch
No relevant relationships to disclose
Ian E. Smith
Honoraria - Roche
Luca Gianni
Consultant or Advisory Role - Roche
Jose Baselga
Consultant or Advisory Role - Roche
Christian Jackisch
Honoraria - Roche
David A. Cameron
Consultant or Advisory Role - Roche
Richard Bell
Consultant or Advisory Role - Roche
Brian Leyland-Jones
No relevant relationships to disclose
Mitchell Dowsett
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Richard D. Gelber
Research Funding - Roche
Martine J. Piccart-Gebhart
Consultant or Advisory Role - Roche/Genentech
Thomas Suter
Research Funding - Roche
Other Remuneration - Roche